HTML Microdata document

This HTML5 document contains 89 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/kegg-drug/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/drugbank/
n15	http://linked.opendata.cz/resource/AHFS/
foaf	http://xmlns.com/foaf/0.1/
n5	http://linked.opendata.cz/resource/drugbank/company/
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/national-drug-code-directory/
n27	http://linked.opendata.cz/resource/drugbank/dosage/
n25	http://linked.opendata.cz/resource/drugbank/mixture/
n13	http://www.drugs.com/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/chemspider/
n10	http://bio2rdf.org/drugbank:
n21	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/chebi/
adms	http://www.w3.org/ns/adms#
n28	http://www.rxlist.com/cgi/generic/
n16	http://linked.opendata.cz/resource/drugbank/patent/
n26	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/wikipedia/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n11	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/pharmgkb/
n6	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n4	http://linked.opendata.cz/resource/drugbank/property/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/pubchem-compound/
xsdh	http://www.w3.org/2001/XMLSchema#
n17	http://linked.opendata.cz/resource/drugbank/drug/DB00973/identifier/pubchem-substance/
n19	http://linked.opendata.cz/resource/atc/
n14	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00973
rdf:type: n3:Drug
n3:description: Ezetimibe is an anti-hyperlipidemic medication which is used to lower cholesterol levels. Specifically, it appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes.
n3:dosage: n27:271B46C6-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132-7. Epub 2005 May 31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15928087
n3:group: approved
n3:halfLife: 22 hours (both ezetimibe and ezetimibe-glucuronide).
n3:indication: For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
n3:manufacturer: n5:271B46C4-363D-11E5-9242-09173F13E4C5
owl:sameAs: n10:DB00973 n26:DB00973
dcterms:title: Ezetimibe
adms:identifier: n8:Ezetimibe n11:PA10816 n17:46507625 n18:66582-414-31 n20:150311 n21:49040 n22:D01966 n23:132493 n24:DB00973
n3:mechanismOfAction: Ezetimibe localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol. This leads to a decrease in the delivery of intestinal cholesterol to the liver.
n3:packager: n5:271B46B7-363D-11E5-9242-09173F13E4C5 n5:271B46B8-363D-11E5-9242-09173F13E4C5 n5:271B46B5-363D-11E5-9242-09173F13E4C5 n5:271B46B6-363D-11E5-9242-09173F13E4C5 n5:271B46BF-363D-11E5-9242-09173F13E4C5 n5:271B46C0-363D-11E5-9242-09173F13E4C5 n5:271B46BD-363D-11E5-9242-09173F13E4C5 n5:271B46BE-363D-11E5-9242-09173F13E4C5 n5:271B46BB-363D-11E5-9242-09173F13E4C5 n5:271B46BC-363D-11E5-9242-09173F13E4C5 n5:271B46B9-363D-11E5-9242-09173F13E4C5 n5:271B46BA-363D-11E5-9242-09173F13E4C5 n5:271B46C3-363D-11E5-9242-09173F13E4C5 n5:271B46C1-363D-11E5-9242-09173F13E4C5 n5:271B46C2-363D-11E5-9242-09173F13E4C5
n3:patent: n16:5846966 n16:7030106 n16:2172149
n3:routeOfElimination: 78% of the dose is excreted into feces. 11% of the dose is excreted into urine. Ezetimibe was the major component in feces and accounted for 69% of the administered dose, while ezetimibe-glucuronide was the major component in urine and accounted for 9% of the administered dose.
n3:synonym: Ezetimibum Ezetimiba Ezedoc Zetia Ezetrol
n3:toxicity: The most common adverse reactions in the group of patients treated with ezetimibe that led to treatment discontinuation and occurred at a rate greater than placebo were, arthralgia (0.3%), dizziness (0.2%), and gamma-glutamyltransferase increase (0.2%).
n14:hasAHFSCode: n15:24-06-05
n3:foodInteraction: Take without regard to meals.
n3:mixture: n25:271B46B3-363D-11E5-9242-09173F13E4C5 n25:271B46B4-363D-11E5-9242-09173F13E4C5
n3:proteinBinding: >90% bound to human plasma protein
n3:synthesisReference: Venkataraman Sundaram, Srinivasam Rajan, Vaddadi Ramayya, Sunkara Vardhan, Bulusu Subrahmanyam, Cheemalapati Sasikala, "Polymorphs of ezetimibe and process for preparation thereof." U.S. Patent US20050171080, issued August 04, 2005.
foaf:page: n13:ezetimibe.html n28:ezetimibe.htm
n3:IUPAC-Name: n4:271B46CB-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B46D1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B46D0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B46CD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B46CE-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B46CF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B46E1-363D-11E5-9242-09173F13E4C5 n4:271B46C9-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B46E3-363D-11E5-9242-09173F13E4C5 n4:271B46CA-363D-11E5-9242-09173F13E4C5 n4:271B46C7-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B46C8-363D-11E5-9242-09173F13E4C5
n14:hasATCCode: n19:C10AX09
n3:H-Bond-Acceptor-Count: n4:271B46D7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B46D8-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B46D2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B46D3-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B46D5-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B46D4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B46D6-363D-11E5-9242-09173F13E4C5
n3:absorption: After oral administration, ezetimibe is absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). When a single 10 mg dose of ezetimibe is given to a fasted, male, adult subject, the pharmacokinetic parameters are as follows: Cmax = 3.5 - 5.5 ng/mL; Tmax = 4- 12 hours. The pharmacokinetic parameters for ezetimibe-glucuronide are as follows: Cmax = 45 - 71 ng/mL; Tmax = 1-2 hours. Food has not impact on the extent of absorption of ezetimibe. However, Cmax increases by 38% with a high-fat meal.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 163222-33-1
n3:category
n3:containedIn: n6:271B46C5-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n4:271B46DD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B46DF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B46E0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n4:271B46E2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B46DC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B46DB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B46DE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B46CC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B46D9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B46DA-363D-11E5-9242-09173F13E4C5